Ferrara N. . .The Biology of VEGF and Its Receptors. Nature Medicine, 9(2003) : 669-676.
Holmes K. .2007 .Vascular Endothelial Growth Factor Receptor-2: Structure. Intracellular Signalling and Therapeutic Inhibition.” Cellular Signalling, 19 : 2003-2012.
Shibuya M.,Pro-Angiogenic Therapies M. . .Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-. ” Genes and Cancer, 2(2011) : 1097-1105.
Shibuya M. .2013 .Vascular Endothelial Growth Factor and Its Receptor System: Physiological Functions in Angiogenesis and Pathological Roles in Various Diseases. ” Journal of Biochemistry, 153 : 13-19.
Olsson A.K. . .. VEGF Receptor Signalling-In Control of Vascular Function.” Nature Reviews Molecular Cell Biology, 7(2006) : 359-371.
Simons M. .2016 .Mechanisms and Regulation of Endothelial VEGF Receptor Signalling. Nature Reviews Molecular Cell Biology, 17 : 611-625.
McTigue M. . .Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. ” Structure, 7(1999) : 319-330.
Liu X. . .ANGPTL2/LILRB2 Signaling Promotes the Propagation of Lung Cancer Cells. ” Oncotarget, 6(2015) : 21004-21015.
Rafii S.,Lyden D. .2008 .Cancer: A Few to Flip the Angiogenic Switch. Science, 319 : 163-164.
Matsumoto T. .2005 .VEGF Receptor-2 Y951 Signaling and a Role for the Adapter Molecule TSAd in Tumor Angiogenesis. EMBO Journal, 24 : 2342-2353.
Kowanetz M.,Ferrara N. .2006 .. Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective.” Clinical Cancer Research, 12 : 5018-5022.
Fuchs C.S. .2014 .Phase 3 Trial.” The Lancet. , 383 : 31-39.
Llovet J.M. .2008 .. Sorafenib in Advanced Hepatocellular Carcinoma.” New England Journal of Medicine, 359 : 378-390.
Leong A.,Kim M. .2020 .The Angiopoietin-2 and Tie Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. International Journal of Molecular Sciences, 21 : 1-20.
Moserle L.,Casanovas O. .2013 .Anti-Angiogenesis and Metastasis: A Tumour and Stromal Cell Alliance. ” Journal of Internal Medicine, 273 : 128-137.
Casanovas O. . .Drug Resistance by Evasion of Antiangiogenic Targeting of VEGF Signaling in Late-Stage Pancreatic Islet Tumors. ” Cancer Cell, 8(2005) : 299-309.
López-Lázaro M.,Current Medicinal Chemistry-Anti-Cancer Agents . .Flavonoids as Anticancer Agents: Structure-Activity Relationship Study. , 2(2002) : 691-714.
Bisht S. .2007 .Polymeric Nanoparticle-Encapsulated Curcumin ('Nanocurcumin'): A Novel Strategy for Human Cancer Therapy. ” Journal of Nanobiotechnology, 5 : .
Madadi N.R. .2015 .Synthesis and Evaluation of a Series of Resveratrol Analogues as Potent Anti-Cancer Agents That Target Tubulin. MedChemComm, 6 : .
Patel N. .2025 .Investigating the Role of Natural Flavonoids in VEGFR Inhibition: Molecular Modelling and Biological Activity in A549 Lung Cancer Cells. ” Journal of Molecular Structure, 1322 : 140392.
Zhang Y. .2020 .Phytochemicals of Garlic: Promising Candidates for Cancer Therapy. ” Biomedicine and Pharmacotherapy, 123 : 109730.
Talib W.H. .2024 .. Allicin and Cancer Hallmarks.” Molecules, 29 : .
Xiao D. .2006 .Diallyl Trisulfide Inhibits Angiogenic Features of Human Umbilical Vein Endothelial Cells by Causing Akt Inactivation and Down-Regulation of VEGF and VEGF-R2.” Nutrition and Cancer. , 55 : 94-107.